Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Financial News

Qiming backs Abbisko in $42M series B

Hongjiang Li, Staff Writer
March 21, 2019 11:01 PM UTC

Abbisko raised a $42 million series B round led by new investor Qiming Venture Partners to advance its oncology compounds into the clinic and further expand its discovery pipeline.

Abbisko Therapeutics Co. Ltd. (Shanghai, China) plans to start Phase I trials of ABSK011 and ABSK021, its most advanced compounds, in the coming months. ABSK011 and ABSK021 are small molecule inhibitors of FGFR4 for hepatocellular carcinoma (HCC) and CSF1R for solid tumors, respectively...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Abbisko Therapeutics Co. Ltd.